CRM Publications

Blake SM, Stricker SH, Halavach H, Poetsch AR, Cresswell G, Kelly G, Kanu N, Marino S, Luscombe NM, Pollard SM et al..  2016.  Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation.Elife. 5

Ding Y, Hubert CG, Herman J, Corrin P, Toledo CM, Skutt-Kakaria K, Vazquez J, Basom R, Zhang B, Risler JK et al..  2013.  Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells.Cancer Discov. 3(2):198-211.

Hubert CG, Bradley RK, Ding Y, Toledo CM, Herman J, Skutt-Kakaria K, Girard EJ, Davison J, Berndt J, Corrin P et al..  2013.  Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A.Genes Dev. 27(9):1032-45.

Carén H, Pollard SM, Beck S.  2013.  The good, the bad and the ugly: epigenetic mechanisms in glioblastoma.Mol Aspects Med. 34(4):849-62.

Stricker SH, Feber A, Engström PG, Carén H, Kurian KM, Takashima Y, Watts C, Way M, Dirks P, Bertone P et al..  2013.  Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner.Genes Dev. 27(6):654-69.

Natalwala A, Bharkhada V, Noel G, Cruickshank G.  2011.  Comparison of time taken from initial presentation to histological diagnosis of Glioblastoma Multiforme (GBM) in Birmingham, United Kingdom and Strasbourg, France.Clin Neurol Neurosurg. 113(5):358-61.